The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
In vivo activity of nuclease-resistant siRNAs
Open accessAbstract
Chemical modifications have been incorporated into short interfering RNAs (siRNAs) without reducing their ability to inhibit gene expression in mammalian cells grown in vitro. In this study, we begin to assess the potential utility of 2′-modified siRNAs in mammals. We demonstrate that siRNA modified with 2′-flouro (2′-F) pyrimidines are functional in cell culture and have a greatly increased stability and a prolonged half-life in human plasma as compared to 2′-OH containing siRNAs. Moreover, we show that the 2′-F containing siRNAs are functional in mice and can inhibit the expression of a target gene in vivo. However, even though the modified siRNAs have greatly increased resistance to nuclease degradation in plasma, this increase in stability did not translate into enhanced or prolonged inhibitory activity of target gene reduction in mice following tail vein injection. Thus, this study shows that 2′-F modified siRNAs are functional in vivo, but that they are not necessarily more potent than unmodified siRNAs in animals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429 · cited 1×
“The RNAi phenomenom was originally discovered in Caenorhabditis elegans in which delivery of only a few molecules of double-stranded RNA (dsRNA) per cell can engender gene-specific silencing throughout the entire organism and its progeny (Fire et al. 1998).”
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Role for a bidentate ribonuclease in the initiation step of RNA interference
Bernstein, E., Caudy, A. A., Hammond, S. M., & Hannon, G. J. (2001) · Nature · doi:10.1038/35053110 · Cited by 4,892
Hannon, G. J. (2002) · Nature · doi:10.1038/418244a · Cited by 3,538
A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants
Hamilton, A. J., & Baulcombe, D. C. (1999) · Science · doi:10.1126/science.286.5441.950 · Cited by 3,041
An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells
Hammond, S. M., Bernstein, E., Beach, D., & Hannon, G. J. (2000) · Nature · doi:10.1038/35005107 · Cited by 3,003
Zamore, P. D., Tuschl, T., Sharp, P. A., & Bartel, D. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80620-0 · Cited by 2,676
Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA
Liu, F., Song, Y. K., & Liu, D. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300947 · Cited by 1,727
Gene silencing in mammals by small interfering RNAs
McManus, M. T., & Sharp, P. A. (2002) · Nature Reviews Genetics · doi:10.1038/nrg908 · Cited by 1,399
Killing the messenger: short RNAs that silence gene expression
Dykxhoorn, D. M., Novina, C. D., & Sharp, P. A. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1129 · Cited by 1,182
Cited by
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
The chemical evolution of oligonucleotide therapies of clinical utility
Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216
Interfering with disease: a progress report on siRNA-based therapeutics
de Fougerolles, A., Vornlocher, H.-P., Maraganore, J., & Lieberman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2310 · Cited by 1,203
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,168
siRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081
Unlocking the potential of the human genome with RNA interference
Hannon, G. J., & Rossi, J. J. (2004) · Nature · doi:10.1038/nature02870 · Cited by 1,064
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S.-K., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,021
Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras
McNamara, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., & Giangrande, P. H. (2006) · Nature Biotechnology · doi:10.1038/nbt1223 · Cited by 1,002
Self-citationRevealing the world of RNA interference
Mello, C. C., & Conte, D. (2004) · Nature · doi:10.1038/nature02872 · Cited by 997
Schiffelers, R. M. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh140 · Cited by 901
In vivo imaging of siRNA delivery and silencing in tumors
Medarova, Z., Pham, W., Farrar, C., Petkova, V., & Moore, A. (2007) · Nature Medicine · doi:10.1038/nm1486 · Cited by 697
Progress towards in Vivo Use of siRNAs
Behlke, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.001 · Cited by 677
siRNA vs. shRNA: Similarities and differences
Rao, D. D., Vorhies, J. S., Senzer, N., & Nemunaitis, J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.004 · Cited by 660
siRNA delivery systems for cancer treatment
Oh, Y.-K., & Park, T. G. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.018 · Cited by 645
Lipid nanoparticles enabling gene therapies: from concepts to clinical utility
Kulkarni, J. A., Cullis, P. R., & van der Meel, R. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0721 · Cited by 592
Bartlett, D. W. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj439 · Cited by 592
RNA Interference in Vitro and in Vivo Using a Novel Chitosan/siRNA Nanoparticle System
Howard, K. A., Rahbek, U. L., Liu, X., Damgaard, C. K., Glud, S. Z., Andersen, M. Ø., Hovgaard, M. B., Schmitz, A., Nyengaard, J. R., Besenbacher, F., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.04.010 · Cited by 585
Design of Noninflammatory Synthetic siRNA Mediating Potent Gene Silencing in Vivo
Judge, A. D., Bola, G., Lee, A. C. H., & MacLachlan, I. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.002 · Cited by 571
Hu-Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E., & Triche, T. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0565 · Cited by 567
Lipid-based systemic delivery of siRNA
Tseng, Y.-C., Mozumdar, S., & Huang, L. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.003 · Cited by 463
Chemical Modification of siRNAs for In Vivo Use
Behlke, M. A. (2008) · Oligonucleotides · doi:10.1089/oli.2008.0164 · Cited by 454
Robbins, M., Judge, A., & MacLachlan, I. (2009) · Oligonucleotides · doi:10.1089/oli.2009.0180 · Cited by 449
Allerson, C. R., Sioufi, N., Jarres, R., Prakash, T. P., Naik, N., Berdeja, A., Wanders, L., Griffey, R. H., Swayze, E. E., & Bhat, B. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049167j · Cited by 448
Chemically modified siRNA: tools and applications
Watts, J. K., Deleavey, G. F., & Damha, M. J. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.05.007 · Cited by 431
RNA interference: From gene silencing to gene-specific therapeutics
Leung, R. K. M., & Whittaker, P. A. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.03.004 · Cited by 382
Bramsen, J. B., Laursen, M. B., Nielsen, A. F., Hansen, T. B., Bus, C., Langkjær, N., Babu, B. R., Højland, T., Abramov, M., Van Aerschot, A., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp106 · Cited by 369
Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo
Takeshita, F., Minakuchi, Y., Nagahara, S., Honma, K., Sasaki, H., Hirai, K., Teratani, T., Namatame, N., Yamamoto, Y., Hanai, K., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501753102 · Cited by 355
Chemical modification of siRNAs to improve serum stability without loss of efficacy
Choung, S., Kim, Y. J., Kim, S., Park, H.-O., & Choi, Y.-C. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.02.049 · Cited by 348
Hydrodynamic Gene Delivery: Its Principles and Applications
Suda, T., & Liu, D. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300314 · Cited by 347
RNA interference and chemically modified small interfering RNAs
Manoharan, M. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.10.007 · Cited by 346
The Silent Revolution: RNA Interference as Basic Biology, Research Tool, and Therapeutic
Dykxhoorn, D. M., & Lieberman, J. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104606 · Cited by 336
The silent treatment: siRNAs as small molecule drugs
Dykxhoorn, D. M., Palliser, D., & Lieberman, J. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302703 · Cited by 324
Synthetic materials at the forefront of gene delivery
Lostalé-Seijo, I., & Montenegro, J. (2018) · Nature Reviews Chemistry · doi:10.1038/s41570-018-0039-1 · Cited by 310
Efficient and targeted delivery of siRNA in vivo
Shim, M. S., & Kwon, Y. J. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07904.x · Cited by 309
Novel Dual Inhibitory Function Aptamer–siRNA Delivery System for HIV-1 Therapy
Zhou, J., Li, H., Li, S., Zaia, J., & Rossi, J. J. (2008) · Molecular Therapy · doi:10.1038/mt.2008.92 · Cited by 301
Engineering RNA for Targeted siRNA Delivery and Medical Application
Guo, P., Coban, O., Snead, N. M., Trebley, J., Hoeprich, S., Guo, S., & Shu, Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.008 · Cited by 300
RNA interference against viruses: strike and counterstrike
Haasnoot, J., Westerhout, E. M., & Berkhout, B. (2007) · Nature Biotechnology · doi:10.1038/nbt1369 · Cited by 295
siRNA therapeutics: a clinical reality
Saw, P. E., & Song, E.-W. (2020) · Science China Life Sciences · doi:10.1007/s11427-018-9438-y · Cited by 291
Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication†
Morrissey, D. V., Blanchard, K., Shaw, L., Jensen, K., Lockridge, J. A., Dickinson, B., McSwiggen, J. A., Vargeese, C., Bowman, K., Shaffer, C. S., et al. (2005) · Hepatology · doi:10.1002/hep.20702 · Cited by 290
Christiaens, O., Swevers, L., & Smagghe, G. (2014) · Peptides · doi:10.1016/j.peptides.2013.12.014 · Cited by 289
Positional Effect of Chemical Modifications on Short Interference RNA Activity in Mammalian Cells
Prakash, T. P., Allerson, C. R., Dande, P., Vickers, T. A., Sioufi, N., Jarres, R., Baker, B. F., Swayze, E. E., Griffey, R. H., & Bhat, B. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050044o · Cited by 285
Chemical modification: the key to clinical application of RNA interference?
Corey, D. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33483 · Cited by 285
Overcoming the Innate Immune Response to Small Interfering RNA
Judge, A., & MacLachlan, I. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.179 · Cited by 284
Physicochemical and Biological Characterization of Targeted, Nucleic Acid-Containing Nanoparticles
Bartlett, D. W., & Davis, M. E. (2007) · Bioconjugate Chemistry · doi:10.1021/bc0603539 · Cited by 283
RNAi-based drug design: considerations and future directions
Tang, Q., & Khvorova, A. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00912-9 · Cited by 282
Recent advances in hepatocellular carcinoma therapy
Dutta, R., & Mahato, R. I. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.010 · Cited by 280
Action and Reaction: The Biological Response to siRNA and Its Delivery Vehicles
Kanasty, R. L., Whitehead, K. A., Vegas, A. J., & Anderson, D. G. (2012) · Molecular Therapy · doi:10.1038/mt.2011.294 · Cited by 279
Nair, J. K., Attarwala, H., Sehgal, A., Wang, Q., Aluri, K., Zhang, X., Gao, M., Liu, J., Indrakanti, R., Schofield, S., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx818 · Cited by 278
Advances in siRNA delivery in cancer therapy
Singh, A., Trivedi, P., & Jain, N. K. (2018) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2017.1307210 · Cited by 271
Drug delivery of siRNA therapeutics: potentials and limits of nanosystems
Reischl, D., & Zimmer, A. (2009) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2008.06.001 · Cited by 253
Lipid nanoparticles for short interfering RNA delivery
Leung, A. K. K., Tam, Y. Y. C., & Cullis, P. R. (2014) · Advances in genetics · doi:10.1016/b978-0-12-800148-6.00004-3 · Cited by 158
Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering
Bramsen, J. B., & Kjems, J. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00154 · Cited by 92
“…et al., 2003; Prakash et al., 2005; Choung et al., 2006; Manoharan et al., 2011) and substitution of all siRNA pyrimidines was reported to greatly enhance serum stability and to support effective silencing in vitro and in vivo (Capodici et al., 2002; Layzer et al., 2004; Morrissey et al., 2005a).”
BackgroundInfluentialde Paula Brandão, P. R., Titze-de-Almeida, S. S., & Titze-de-Almeida, R. (2020) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00438-6 · Cited by 72
GalNac-siRNA conjugate delivery technology promotes the treatment of typical chronic liver diseases
Qin, Z.-X., Zuo, L., Zeng, Z., Ma, R., Xie, W., Zhu, X., & Zhou, X. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2466767 · Cited by 32
Shin, S., Kim, Y. S., Kim, J., Kwon, H.-M., Kim, D.-E., & Hah, S. S. (2013) · Nucleic Acid Therapeutics · doi:10.1089/nat.2012.0396 · Cited by 9
Metadata
- Authors
- LAYZER, J. M., MCCAFFREY, A. P., TANNER, A. K., HUANG, Z., KAY, M. A., & SULLENGER, B. A.
- Venue
- RNA
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2004-04-20
- Volume
- 10
- Issue
- 5
- Pages
- 766-771
- ISSN
- 1355-8382 (ISSN-L)
- 1469-9001
- OpenAlex
- W2111066814
- Cited by
- 580
- References
- 27
- FWCI
- 11.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.